Research Analysts Issue Forecasts for CRBU FY2025 Earnings

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Investment analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Caribou Biosciences in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst R. Bienkowski expects that the company will post earnings of ($1.31) per share for the year. The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.64) per share.

CRBU has been the subject of a number of other research reports. HC Wainwright reiterated a “buy” rating and issued a $9.00 price target on shares of Caribou Biosciences in a research note on Friday, November 15th. Bank of America cut their price objective on shares of Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Finally, Citigroup reduced their price target on shares of Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, November 26th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $10.33.

Caribou Biosciences Price Performance

Shares of Caribou Biosciences stock opened at $1.51 on Thursday. The stock has a market capitalization of $136.73 million, a PE ratio of -0.92 and a beta of 2.34. Caribou Biosciences has a 1-year low of $1.47 and a 1-year high of $8.33. The company’s fifty day simple moving average is $1.83 and its 200-day simple moving average is $1.99.

Caribou Biosciences (NASDAQ:CRBU) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.06. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. The company had revenue of $2.02 million during the quarter, compared to analysts’ expectations of $3.37 million.

Institutional Trading of Caribou Biosciences

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Renaissance Technologies LLC acquired a new position in Caribou Biosciences during the 2nd quarter valued at about $2,432,000. Dimensional Fund Advisors LP increased its holdings in shares of Caribou Biosciences by 25.7% during the second quarter. Dimensional Fund Advisors LP now owns 2,623,283 shares of the company’s stock valued at $4,302,000 after acquiring an additional 536,162 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Caribou Biosciences by 6.5% in the 3rd quarter. Geode Capital Management LLC now owns 2,030,443 shares of the company’s stock valued at $3,980,000 after purchasing an additional 124,782 shares during the last quarter. Exchange Traded Concepts LLC boosted its stake in Caribou Biosciences by 103.5% in the 3rd quarter. Exchange Traded Concepts LLC now owns 82,494 shares of the company’s stock worth $162,000 after purchasing an additional 41,948 shares in the last quarter. Finally, Barclays PLC grew its position in Caribou Biosciences by 122.4% during the 3rd quarter. Barclays PLC now owns 129,839 shares of the company’s stock worth $255,000 after purchasing an additional 71,463 shares during the last quarter. Hedge funds and other institutional investors own 77.51% of the company’s stock.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.